Ultrafast Liquid Chromatographic Method Development and its Validation for Quantification of Telaprevir in Pharmaceutical Dosage Form by Using Quality by Design Approach.
Quality by design (QbD) approach thrives to achieve an assured and predicted quality product. A stability-indicating reversed phase ultrafast liquid chromatographic method was developed using the principles of QbD to quantify telaprevir (TEL) in pharmaceutical dosage form. A Box-Behnken experimental design was employed for identifying optimum chromatographic conditions by assessing the method robustness by selecting organic phase composition (%), mobile phase flow rate (mL/min) and pH of the borate buffer as the factors, to study their effect on the responses like retention time, theoretical plate count and tailing factor. Chromatographic separation was achieved on Enable-C18G (250 × 4.6 mm i.d., 5 µm) column using methanol: borate buffer of pH 9.0 (90 : 10, v/v) as mobile phase at a flow rate of 1.2 mL/min and PDA detection at 270 nm. Establishment of calibration curve yielded linearity in the range of 5-70 µg/mL along with values of accuracy and precision within the acceptance limit of mean percent recoveries between 98.9 and 100.7%. Limit of detection and limit of quantitation were found to be 1.60 and 4.75 µg/mL. Analysis of system suitability yielded high degree of method reproducibility and robustness. The developed method showed high specificity for TEL and its degradation products formed during forced degradation conditions. The developed method also demonstrated suitability for routine analysis of TEL in bulk drug and pharmaceutical dosage forms.